# Understanding MDCG Guidance on Differentiating Medical Devices from Medicinal Products: An Overview
The healthcare industry is a complex ecosystem where medical devices and medicinal products play critical roles in diagnosing, treating, and managing diseases. However, the distinction between these two categories is not always clear-cut, leading to regulatory challenges for manufacturers, healthcare providers, and regulatory authorities. To address this, the Medical Device Coordination Group (MDCG) has issued guidance to help stakeholders differentiate between medical devices and medicinal products. This article provides an overview of the MDCG guidance, its significance, and its implications for the healthcare industry.
—
## What is the MDCG?
The Medical Device Coordination Group (MDCG) is a European advisory body established under the EU Medical Device Regulation (MDR) 2017/745 and the In Vitro Diagnostic Medical Device Regulation (IVDR) 2017/746. Comprising representatives from EU Member States and the European Commission, the MDCG provides guidance and support to ensure the consistent implementation of these regulations across the European Union.
One of the MDCG’s key responsibilities is to clarify regulatory requirements and address ambiguities, such as the distinction between medical devices and medicinal products. This is particularly important given the increasing convergence of technologies and the emergence of combination products that blur traditional boundaries.
—
## Why is Differentiation Important?
The distinction between medical devices and medicinal products is critical because these categories are subject to different regulatory frameworks in the EU:
– **Medical Devices** are regulated under the MDR and IVDR. These products are typically instruments, apparatuses, or software intended for medical purposes, such as diagnosis, prevention, monitoring, or treatment of diseases.
– **Medicinal Products** are regulated under Directive 2001/83/EC and Regulation (EC) No 726/2004. These products are substances or combinations of substances intended to treat or prevent disease, or to restore, correct, or modify physiological functions through pharmacological, immunological, or metabolic means.
The regulatory pathway determines the requirements for clinical evaluation, conformity assessment, labeling, and post-market surveillance. Misclassification can lead to non-compliance, delays in market access, and potential safety risks for patients.
—
## Key Points from the MDCG Guidance
The MDCG guidance provides a structured approach to differentiating medical devices from medicinal products. Below are the key points outlined in the guidance:
### 1. **Primary Mode of Action (PMOA)**
The primary mode of action is the most critical factor in determining whether a product is a medical device or a medicinal product. According to the guidance:
– If the product achieves its intended purpose primarily through **pharmacological, immunological, or metabolic means**, it is classified as a medicinal product.
– If the product achieves its intended purpose primarily through **physical, mechanical, or other non-pharmacological means**, it is classified as a medical device.
For example, a drug-coated stent is classified as a medical device because its